OSL.XA - OncoSil Medical Limited

OncoSil Medical Limited

15 Blue Street
Suite 503 Level 5
North Sydney, NSW 2060
Australia
61 2 9223 3344
https://www.oncosil.com.au

Sector(s): 
Industry: 
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Nigel Lange	CEO, MD & Director	388.2k	N/A	N/A
Mr. Michael Warrener	Global Sales & Marketing Director	N/A	N/A	N/A
Dr. David Charles James	Global Head of Manufacturing Operations	N/A	N/A	N/A
Dr. Ralph Peters	Chief Medical Officer	N/A	N/A	N/A
Mr. David Turner	Head of Medical Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in May 2013. OncoSil Medical Limited was incorporated in 2005 and is headquartered in North Sydney, Australia.

Corporate governance

OncoSil Medical Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.